A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorEli Lilly and Company
About this trial
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.
Eligibility criteria
Qualifiers
Have overweight or obesity, but are otherwise overtly healthy.
Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)/square meter (m²), inclusive.
Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.
Disqualifiers
Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of the following at screening
A fasting plasma glucose concentration greater than or equal to 126 milligrams (mg)/deciliter (dL) or 7.0 millimoles (mmol)/liter (L), or
Hemoglobin A1C (HbA1c) greater than or equal to 6.5% or 48 mmol/mole (mol).
Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, and bipolar disorder, within the last 2 years.
Trial design
Treatments tested in this trial
- Eloralintide
- Placebo
- Acetaminophen
Treatment groups
56 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov